Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on June 14, 2017, 10:03:14 am
-
AbbVie’s investigational hepatitis C virus (HCV) regimen glecaprevir/pibrentasvir, known as G/P, has posted excellent cure rates for those with all genotypes of the virus who did not have cirrhosis, MedPage Today reports. A pooled analysis from major trials of the treatment found that cure rates were comparable between those treated for eight and 12 weeks.
The FDA currently has G/P under priority review. A decision is expected in late June.
Read more...
https://www.hepmag.com/article/just-8-weeks-abbvies-gp-may-cure-hep-c